Katherine Stueland sold $4.2M of WGS
Chief Executive Officer at GeneDx Holdings Corp.. 46,594 shares at an average of $89.62, traded Apr 9, 2025, filed Apr 10, 2025.
Score components
- +25RoleCEO
- +25Trade size$4.2M at market
- +20Share of holdings soldSold 96% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -36.1%, 3m -6.2%, 6m +36.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-010535, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,024 | $81.16 | $164k | 46,290 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,134 | $82.17 | $258k | 43,156 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,297 | $83.25 | $274k | 39,859 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,745 | $84.28 | $231k | 37,114 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,175 | $85.44 | $271k | 33,939 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -5,855 | $86.34 | $506k | 28,084 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -373 | $87.30 | $33k | 27,711 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -300 | $88.70 | $27k | 27,411 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,600 | $90.13 | $144k | 25,811 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,900 | $91.27 | $173k | 23,911 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,000 | $92.28 | $92k | 22,911 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -9,628 | $93.33 | $899k | 13,283 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -4,511 | $94.55 | $427k | 8,772 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,173 | $95.51 | $303k | 5,599 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,174 | $96.29 | $306k | 2,425 | Apr 10, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -705 | $97.24 | $69k | 1,720 | Apr 10, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 28Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $227k 3,729 shares | -9% | |
| 38Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $638k 10,501 shares | -9% | |
| 23Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $68k 1,266 shares | -3% | |
| 30Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $196k 3,639 shares | -4% | |
| 56Moderate | WGSbuy GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $11M 200,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.